BIOMAT Database Logo BIOMAT Database Logo

Insulin response after treatment depends on fasting plasma glucose level in NIDDM. 1994

K Matsumoto, and S Akazawa, and N Abiru, and M Yano, and M Ishibasi, and S Uotani, and H Matsuo, and E Kawasaki, and H Yamasaki, and H Yamamoto
First Department of Internal Medicine, Nagasaki University School of Medicine, Japan.

We investigated the relationship between the improvement in insulin secretion and glycemic control in non-insulin-dependent diabetes mellitus (NIDDM). Fifty-two patients were classified into three groups according to their pretreatment fasting plasma glucose (FPG) level: Group A, FPG < 7.8 mM, n = 20; Group B, 7.8 mM < or = FPG < 11.1 mM, n = 17; and Group C, 11.1 mM < or = FPG, n = 15. A 75-g oral glucose tolerance test (OGTT) and a glucagon loading test were performed to evaluate insulin secretion before and after treatment. Plasma glucose levels during a 75-g OGTT were decreased significantly after treatment in all groups (P < 0.01). In Group A, there was no significant change in insulin secretion before and after treatment (1466 +/- 213 pM to 1565 +/- 191 pM, P = 0.35). In contrast, in Groups B and C, insulin secretion was poor and suppressed initially, but increased significantly when good glycemic control was obtained after treatment (respectively, 587 +/- 70 pM to 863 +/- 79 pM, P < 0.01, and 621 +/- 94 pM to 1236 +/- 232 pM, P < 0.01). The degree of improvement in insulin secretion in 75-g OGTT correlated positively with the degree of improvement in FPG level after treatment (r = 0.5, P < 0.001). However, the C-peptide response to glucagon did not change before and after treatment. In conclusion, impaired insulin secretion recovered by the good glycemic control in NIDDM with FPG levels above 7.8 mM. Therefore, strict glycemic control (FPG below 7.8 mM) seems important for maintaining good insulin secretion.

UI MeSH Term Description Entries
D007328 Insulin A 51-amino acid pancreatic hormone that plays a major role in the regulation of glucose metabolism, directly by suppressing endogenous glucose production (GLYCOGENOLYSIS; GLUCONEOGENESIS) and indirectly by suppressing GLUCAGON secretion and LIPOLYSIS. Native insulin is a globular protein comprised of a zinc-coordinated hexamer. Each insulin monomer containing two chains, A (21 residues) and B (30 residues), linked by two disulfide bonds. Insulin is used as a drug to control insulin-dependent diabetes mellitus (DIABETES MELLITUS, TYPE 1). Iletin,Insulin A Chain,Insulin B Chain,Insulin, Regular,Novolin,Sodium Insulin,Soluble Insulin,Chain, Insulin B,Insulin, Sodium,Insulin, Soluble,Regular Insulin
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D001786 Blood Glucose Glucose in blood. Blood Sugar,Glucose, Blood,Sugar, Blood
D002096 C-Peptide The middle segment of proinsulin that is between the N-terminal B-chain and the C-terminal A-chain. It is a pancreatic peptide of about 31 residues, depending on the species. Upon proteolytic cleavage of proinsulin, equimolar INSULIN and C-peptide are released. C-peptide immunoassay has been used to assess pancreatic beta cell function in diabetic patients with circulating insulin antibodies or exogenous insulin. Half-life of C-peptide is 30 min, almost 8 times that of insulin. Proinsulin C-Peptide,C-Peptide, Proinsulin,Connecting Peptide,C Peptide,C Peptide, Proinsulin,Proinsulin C Peptide
D003924 Diabetes Mellitus, Type 2 A subclass of DIABETES MELLITUS that is not INSULIN-responsive or dependent (NIDDM). It is characterized initially by INSULIN RESISTANCE and HYPERINSULINEMIA; and eventually by GLUCOSE INTOLERANCE; HYPERGLYCEMIA; and overt diabetes. Type II diabetes mellitus is no longer considered a disease exclusively found in adults. Patients seldom develop KETOSIS but often exhibit OBESITY. Diabetes Mellitus, Adult-Onset,Diabetes Mellitus, Ketosis-Resistant,Diabetes Mellitus, Maturity-Onset,Diabetes Mellitus, Non-Insulin-Dependent,Diabetes Mellitus, Slow-Onset,Diabetes Mellitus, Stable,MODY,Maturity-Onset Diabetes Mellitus,NIDDM,Diabetes Mellitus, Non Insulin Dependent,Diabetes Mellitus, Noninsulin Dependent,Diabetes Mellitus, Noninsulin-Dependent,Diabetes Mellitus, Type II,Maturity-Onset Diabetes,Noninsulin-Dependent Diabetes Mellitus,Type 2 Diabetes,Type 2 Diabetes Mellitus,Adult-Onset Diabetes Mellitus,Diabetes Mellitus, Adult Onset,Diabetes Mellitus, Ketosis Resistant,Diabetes Mellitus, Maturity Onset,Diabetes Mellitus, Slow Onset,Diabetes, Maturity-Onset,Diabetes, Type 2,Ketosis-Resistant Diabetes Mellitus,Maturity Onset Diabetes,Maturity Onset Diabetes Mellitus,Non-Insulin-Dependent Diabetes Mellitus,Noninsulin Dependent Diabetes Mellitus,Slow-Onset Diabetes Mellitus,Stable Diabetes Mellitus
D003927 Diet, Diabetic A course of food intake prescribed for patients, that limits the amount of foods with a high GLYCEMIC INDEX. Diabetic Diet,Diabetic Diets,Diets, Diabetic
D005215 Fasting Abstaining from FOOD. Hunger Strike,Hunger Strikes,Strike, Hunger,Strikes, Hunger
D005260 Female Females
D005905 Glyburide An antidiabetic sulfonylurea derivative with actions like those of chlorpropamide Glibenclamide,Daonil,Diabeta,Euglucon 5,Euglucon N,Glybenclamide,HB-419,HB-420,Maninil,Micronase,Neogluconin,HB 419,HB 420,HB419,HB420

Related Publications

K Matsumoto, and S Akazawa, and N Abiru, and M Yano, and M Ishibasi, and S Uotani, and H Matsuo, and E Kawasaki, and H Yamasaki, and H Yamamoto
Plasma glucose and insulin response to macronutrients in nondiabetic and NIDDM subjects.
September 1991, Diabetes care,
K Matsumoto, and S Akazawa, and N Abiru, and M Yano, and M Ishibasi, and S Uotani, and H Matsuo, and E Kawasaki, and H Yamasaki, and H Yamamoto
The fasting plasma glucose cut-point predicting a diabetic 2-h OGTT glucose level depends on the phenotype.
January 2002, Diabetes research and clinical practice,
K Matsumoto, and S Akazawa, and N Abiru, and M Yano, and M Ishibasi, and S Uotani, and H Matsuo, and E Kawasaki, and H Yamasaki, and H Yamamoto
The elevation of serum uric acid depends on insulin resistance but not fasting plasma glucose in hyperuricaemia.
March 2022, Clinical and experimental rheumatology,
K Matsumoto, and S Akazawa, and N Abiru, and M Yano, and M Ishibasi, and S Uotani, and H Matsuo, and E Kawasaki, and H Yamasaki, and H Yamamoto
Effects of fasting on plasma glucose and prolonged tracer measurement of hepatic glucose output in NIDDM.
October 1987, Diabetes,
K Matsumoto, and S Akazawa, and N Abiru, and M Yano, and M Ishibasi, and S Uotani, and H Matsuo, and E Kawasaki, and H Yamasaki, and H Yamamoto
The effect of fasting on plasma insulin after repeated glucose loading in pigs.
September 1972, The Proceedings of the Nutrition Society,
K Matsumoto, and S Akazawa, and N Abiru, and M Yano, and M Ishibasi, and S Uotani, and H Matsuo, and E Kawasaki, and H Yamasaki, and H Yamamoto
Fasting plasma glucose in screening for NIDDM in the U.S. and Israel.
May 1994, Diabetes care,
K Matsumoto, and S Akazawa, and N Abiru, and M Yano, and M Ishibasi, and S Uotani, and H Matsuo, and E Kawasaki, and H Yamasaki, and H Yamamoto
Relationship between hepatic glucose production and fasting plasma glucose concentration in patients with NIDDM.
December 1994, Diabetes,
K Matsumoto, and S Akazawa, and N Abiru, and M Yano, and M Ishibasi, and S Uotani, and H Matsuo, and E Kawasaki, and H Yamasaki, and H Yamamoto
Effect of added fat on plasma glucose and insulin response to ingested potato in individuals with NIDDM.
June 1993, Diabetes care,
K Matsumoto, and S Akazawa, and N Abiru, and M Yano, and M Ishibasi, and S Uotani, and H Matsuo, and E Kawasaki, and H Yamasaki, and H Yamamoto
Lipid profile and its relation to fasting insulin level in non-insulin dependent diabetes mellitus (NIDDM).
August 1995, Bangladesh Medical Research Council bulletin,
K Matsumoto, and S Akazawa, and N Abiru, and M Yano, and M Ishibasi, and S Uotani, and H Matsuo, and E Kawasaki, and H Yamasaki, and H Yamamoto
Effect of inhaled insulin on fasting and postprandial plasma glucose.
June 2007, Annals of internal medicine,
Copied contents to your clipboard!